Evidence map›Paper›PMID 29485237›Full record

ReviewCA: a cancer journal for clinicians2018

Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.

Patrick M Boland, Matthew B Yurgelun, C Richard Boland

Abstract readReview
In one paragraph

Review in CA: a cancer journal for clinicians, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  3. Article
  4. Research progress in diagnosis and treatment of pancreatic cancer with mismatch repair and microsatellite instability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. A novel frameshift variant inFrontiers in medicine · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Genomic characterization of patients with colorectal cancer.Hereditary cancer in clinical practice · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. APhenomics (Cham, Switzerland) · 2025
    Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Patrick M BolandAssistant Professor, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
Matthew B YurgelunAssistant Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
C Richard BolandProfessor, Department of Medicine, University of California at San Diego School of Medicine, San Diego, CA.ORCID 0000-0002-8120-5088

Funding

The Biology and Diagnosis of HNPCCR01CA072851 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI GOEL, AJAY · 1996 to 2019
$6.6M
NCI NIH HHS R01 CA072851
6 · The paper itself

Abstract

The current understanding of familial colorectal cancer was limited to descriptions of affected pedigrees until the early 1990s. A series of landscape-altering discoveries revealed that there were distinct forms of familial cancer, and most were related to genes previously not known to be involved in human disease. This review largely focuses on advances in our understanding of Lynch syndrome because of the unique relationship of this disease to defective DNA mismatch repair and the clinical implications this has for diagnostics, prevention, and therapy. Recent advances have occurred in our understanding of the epidemiology of this disease, and the advent of broad genetic panels has altered the approach to germline and somatic diagnoses for all of the familial colorectal cancer syndromes. Important advances have been made toward a more complete mechanistic understanding of the pathogenesis of neoplasia in the setting of Lynch syndrome, and these advances have important implications for prevention. Finally, paradigm-shifting approaches to treatment of Lynch-syndrome and related tumors have occurred through the development of immune checkpoint therapies for hypermutated cancers. CA Cancer J Clin 2018;68:217-231. © 2018 American Cancer Society.

Indexed as

AdenomaCell Transformation, NeoplasticChemopreventionChemotherapy, AdjuvantColectomyColonoscopyColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisDNA Mutational AnalysisGenetic TestingGerm-Line MutationHumansSequence Analysis, DNAadenomatous polyposis (APC) geneDNA mismatch repairfamilial colorectal cancergenetic testinggermline mutationsimmune checkpoint therapyLynch syndrome

Identifiers

PMID29485237
PMCPMC5980692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.